BACKGROUND: Jumping translocations (JT) are uncommon cytogenetic abnormalities involving nonreciprocal translocations of a single donor chromosome onto 2 or more chromosomes. The clinical characteristics and prognosis of JTs in patients with myeloid malignancies are not well described. MATERIALS AND METHODS: We searched our cytogenetic database from 2003 to 2014 to identify cases of myeloid malignancies associated with a JT. These cases were cross-referenced with our clinical databases to determine patient characteristics, response to treatment and overall survival. RESULTS: We identified 10 patients with myeloid malignancies and a JT: 4 cases of acute myeloid leukemia with myelodysplastic syndrome-related changes, 4 cases of myelodysplastic syndrome, and 2 cases of postpolycythemia myelofibrosis. The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late occurrence, with a median time to JT development of 24.9 months (range, 0-248 months) from diagnosis. The overall response to treatment was poor, with no patients experiencing a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95% confidence interval, 2.5-15.5) after identification of a JT. CONCLUSION: The acquisition of a JT in patients with myeloid malignancies appears to be a late event and is associated with myelodysplasia. In our series, this was associated with a poor prognosis with a poor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival.
BACKGROUND: Jumping translocations (JT) are uncommon cytogenetic abnormalities involving nonreciprocal translocations of a single donor chromosome onto 2 or more chromosomes. The clinical characteristics and prognosis of JTs in patients with myeloid malignancies are not well described. MATERIALS AND METHODS: We searched our cytogenetic database from 2003 to 2014 to identify cases of myeloid malignancies associated with a JT. These cases were cross-referenced with our clinical databases to determine patient characteristics, response to treatment and overall survival. RESULTS: We identified 10 patients with myeloid malignancies and a JT: 4 cases of acute myeloid leukemia with myelodysplastic syndrome-related changes, 4 cases of myelodysplastic syndrome, and 2 cases of postpolycythemia myelofibrosis. The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late occurrence, with a median time to JT development of 24.9 months (range, 0-248 months) from diagnosis. The overall response to treatment was poor, with no patients experiencing a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95% confidence interval, 2.5-15.5) after identification of a JT. CONCLUSION: The acquisition of a JT in patients with myeloid malignancies appears to be a late event and is associated with myelodysplasia. In our series, this was associated with a poor prognosis with a poor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival.
Authors: Vesna Najfeld; Joseph Tripodi; Angela Scalise; Lewis R Silverman; Richard T Silver; Steven Fruchtman; Ronald Hoffman Journal: Br J Haematol Date: 2010-08-25 Impact factor: 6.998
Authors: Giovanni Barosi; Ruben Mesa; Guido Finazzi; Claire Harrison; Jean-Jacques Kiladjian; Eva Lengfelder; Mary F McMullin; Francesco Passamonti; Alessandro M Vannucchi; Carlos Besses; Heinz Gisslinger; Jan Samuelsson; Srdan Verstovsek; Ronald Hoffman; Animesh Pardanani; Francisco Cervantes; Ayalew Tefferi; Tiziano Barbui Journal: Blood Date: 2013-04-16 Impact factor: 22.113
Authors: Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase Journal: Blood Date: 2012-06-27 Impact factor: 22.113
Authors: Vasco Liberal; Hanna-Stina Martinsson-Ahlzén; Jennifer Liberal; Charles H Spruck; Martin Widschwendter; Clare H McGowan; Steven I Reed Journal: Proc Natl Acad Sci U S A Date: 2011-06-22 Impact factor: 11.205
Authors: Irene Sánchez Prieto; Montserrat López Rubio; Eva Arranz; Rosa Ayala; Marta Callejas Charavía; Yolanda Martín Guerrero; Juan José Gil Fernández; Susana Valenciano Martínez; Lucía Castilla García; María Argüello Marina; José María Aspa Cilleruelo; Celia Martínez Vázquez; Julio García Suárez Journal: Case Rep Oncol Date: 2020-09-01